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OBJECTIVES: The six-minute walk test has been widely used to evaluate functional capacity and predict mortality in
several populations. Thus, the aim of this study was to evaluate the prognostic value of the six-minute walk test for
the life expectancy of end-stage renal disease patients.
METHODS: Patients over 18 years old who underwent hemodialysis for at least six months were included. Patients
with hemodynamic instability, smoking, chronic obstructive pulmonary disease, physical incapacity and acute
myocardial stroke in the preceding three months were excluded.
RESULTS: Fifty-two patients (54% males; 36¡11 years old) were followed for 144 months. The distance walked in
the six-minute walk test was a survival predictor for end-stage renal disease patients. In the multivariate analysis, for
each 100 meters walked with a 100-meter increment, the hazard ratio was 0.53, with a 95% confidence interval of
0.37-0.74. There was a positive correlation between the distance walked in the six-minute walk test and peak
oxygen consumption (r = 0.508). In the multivariate analysis, each year of dialysis treatment represented a 10%
increase in death probability; in the severity index analysis, each point on the scale represented an 11% increase in
the death risk.
CONCLUSIONS: We observed that survival increased approximately 5% for every 100 meters walked in the six-
minute walk test, demonstrating that the test is a viable option for evaluating the functional capacity in patients
with end-stage renal disease.
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INTRODUCTION
Chronic kidney disease (CKD) has become a serious
health problem due to its prevalence, high cost, and the
subsequent reductions in life expectancy and quality of life
(1). Cardiovascular disease is the main cause of death in
end-stage renal disease (ESRD) patients, as observed in the
Hypertension Detection and Follow-up Program (2) and the
British Regional Heart Study (3). This result is because these
patients show reduced functional capacity, exercise toler-
ance, resistance and muscle strength compared with
patients with conservatively treated CKD (4).
The peak oxygen consumption (VO2 peak) measurement,
the most used parameter for evaluating functional capacity,
was identified as a strong survival predictor in ESRD (3). In
addition, the six-minute walk test (6MWT) has proved to be
an excellent tool for functional capacity evaluation and has
been widely used in patients with chronic diseases (5-9).
This method has demonstrated prognostic value in pul-
monary hypertension patients (10) and has been considered
to be a predictor of mortality in patients with heart failure
(HF) (6,11). The 6MWT is a sub-maximum effort test that is
more representative of daily life activities than other effort
tests (12) and has low cost and easy applicability (13,14). The
distance walked in the 6MWT shows an association with the
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VO2 peak, making it a viable and safe alternative for
patients who cannot tolerate the ergometric test (11,15,16),
and may also be used as a parameter to evaluate different
therapeutic interventions (17).
The 6MWT has been used to evaluate the functional
capacity of CKD patients (11,18). However, its value as a
mortality predictor has not yet been investigated in this
population. Thus, the aim of this work was to evaluate the
prognostic value of the 6MWT in ESRD patients.
MATERIALS AND METHODS
Research design
This was a prospective cohort study performed with
patients selected by convenience who underwent a regular
hemodialysis program between March 1996 and January
2009 at Santa Lucia Renal Clinic, Cruz Alta/Rio Grande do
Sul (RS) State - Brazil. The ethical and legal aspects of the
project were approved by the Ethics Committee on Research
of the Institute of Cardiology of Rio Grande do Sul/
University Foundation of Cardiology (n˚ 4286/09).
Inclusion and exclusion criteria
The study included patients over 18 years old who were
undergoing hemodialysis treatment for at least six months
and optimized clinical treatment for at least three months
with a complete clinical data record available from a routine
database service. Subjects who had exhibited uncontrolled
hypertension, recent ischemic heart disease (no more than
three months ago), unstable angina, severe cardiac arrhyth-
mias, skeletal disease limiting physical activity and several
respiratory and neurological diseases were excluded from
the study.
Study variables
Variables of functional capacity (distance walked in
6MWT, the ergospirometric test and the ESRD-SI) were
measured at the time the subjects were admitted to the
study in March and April of 1996. The 6MWT was
performed during an inter-dialysis period in a 30 m long
corridor that was demarcated at every meter, and the
patients were assisted by a trained physiotherapist and a
nurse.
The ergospirometry test was also performed in the inter-
dialysis period during the same week as the 6MWT on an
ergometric treadmill (Imbramed Ltd., Brazil) according to
the criteria of the American Heart Association (19) and the
National Consensus on Ergometry (20). The Bruce Modified
Protocol (21,22) and the Ergo–PC13 system (Micromed
Biotecnologia Ltd., USA) were used. The analysis of the
respiratory gases was recorded via the Teem 100 (Aerosport
Ind., USA) metabolic system, which evaluates oxygen
consumption (VO2). Electrocardiographic effort monitoring
occurred with three derivations for recording the ST follow
up. At the end of each stage, blood pressure was measured
with the BORG scale (23).
The ESRD-SI indicates morphologic disease and physio-
logic disturbance rates, measuring the impact of the process
on the patient’s functional and psychological capacity (24).
The patient clinical and demographic characteristics,
including cardiovascular disease risk factors, hemodialysis
time, transplant and death date, were semiannually
updated by consulting the database service, the patients
and/or family members. Mortality data were updated using
patient charts, family members or information obtained
from consulting public registries about patient deaths.
Patient charts were reviewed by two independent investi-
gators. Blood examinations and biochemical analyses were
performed monthly at the hemodialysis unit, and their
results were collected from a routine database.
Follow up
Patients were followed up monthly by a hemodialysis
service team and the researchers, who collected data
regarding laboratory exams, clinical condition and morbid-
ity. Transplants performed or transfers to another city were
updated during the follow-up period, and they were
considered as a census in the survival analysis. The patients
selected for the study underwent hemodialysis regularly
with three sessions per week, with each session lasting
approximately four hours. Data were collected until January
2009.
Statistical analysis
Continuous variables are expressed as averages and
standard deviations, and categorical variables are expressed
in percentages with the 95% confidence interval (CI). Student’s
t test and the Mann-Whitney U test were used when appro-
priate for continuous variables. Categorical variables were
compared using the chi-square test. The Pearson correlation
coefficient was used to correlate the variables. Predictor
variables (ESRD-SI, 6MWT, age, dialysis time and VO2 peak)
and mortality were evaluated for associations using the Cox
univariate andmultivariate models. Variables that were found
to be statistically significant in the univariate and multiva-
riate analyses were used for the model. Data with an alpha
error of 5% (p,0.05) were considered to be significant.
RESULTS
The sample characteristics are shown in Table 1. Of 89
patients initially selected for the study, 16.8% (n= 15) were
excluded due to decompensated ischemic cardiopathy, and
an additional 24.7% (n= 22) were excluded because they
moved to another county and/or refused to continue
undergoing the periodic functional evaluations. A total of
52 patients (Figure 1) were followed up: 21 patients died,
representing a survival index of 59.6%. During the 12-year
follow-up period, 23.1% of the sample underwent a
transplant. Systolic blood pressure was approximately
20 mmHg higher in patients who survived (p= 0.01). The
use of calcium antagonists was approximately 50% higher in
patients (p= 0.037) who died [RR: 2.03; 95% confidence
interval (95% CI): 0.99 – 4.18]. Other biochemical and
pharmacological variables did not differ between the
patients who died or survived (Table 1).
Regarding the relationship between hemodialysis time
and mortality, the univariate and multivariate analyses
indicated a 10% increase in death risk for each year on
hemodialysis, with an odds ratio (OR) of 1.01 and a 95% CI
between 1.00-1.02 (Tables 2 and 3).
The End-Stage Renal Disease Severity Index (ESRD-SI)
was higher in patients who survived until the end of the
study (p=0.002). In the univariate analysis, the ESRD-SI
presented an OR of 1.15, with a 95% CI of 1.08-1.23 (Table 2).
These results were similar to the multivariate analysis, in
which a one-point increase in the score led to an 11%
increase in the death risk (Table 3).
Prognostic value of 6MWT in ESRD
Kohl LM et al.
CLINICS 2012;67(6):581-586
582
The VO2 peak was approximately 50% lower (p,0.001)
than the predicted values for age and gender (Table 1). No
difference was observed in the VO2 peak among patients
who survived and those who died. The VO2 peak did not
differ significantly (univariate and multivariate analyses)
after adjusting for the confounding factors, with the OR for
death equal to 1.04 (95% CI: 0.97–1.13) in the multivariate
analysis (Tables 2 and 3). An association was observed
between the distance walked in the 6MWT and the VO2
peak (Figure 2).
The stratification of distance walked in the 6MWT in 100-
meter intervals showed that the OR for death was 0.79 (95%
CI: 0.62–1.01) in the unadjusted analysis and 0.53 (95% CI:
0.37–0.74) in the adjusted analysis (Tables 2 and 3).
Additionally, for every 100 meters walked, there was a
correction factor of approximately 5.3%.
DISCUSSION
The main findings in our study demonstrate that dialysis
time, ESRD-SI and the distance walked in the 6MWT are
independent predictors for mortality in ESRD patients. For
every 100 meters walked, a protection factor of approxi-
mately 5.3% occurs in relation to life expectancy, and the
6MWT is also associated with the VO2 peak.
Our study demonstrated that the association between
ESRD-SI and life expectancy increases in patients: for each
point obtained in the ESRD score, there is an 11% increase in
death risk. These findings elevate this scale as an indepen-
dent predictor of mortality. We believe that this test is an
effective measure to evaluate and predict the quality of
assistance given to a patient, and it is also useful for
investigating renal disease progression (25). A trend similar
to the ESRD-SI was observed for dialysis time, and a 10%
increase in death probability was verified for every year the
patient remained under treatment.
End-stage renal disease patients show high rates of
hospital admissions and mortality (11). Cardiac complica-
tions cause over 50% of deaths and induce low tolerance to
exercise, which consequently compromises the performance
of daily activities (26). In this population, it is important to
practice physical exercise (aerobic or anaerobic) both
between and during dialysis sessions because it reduces
the deleterious effects of this condition (27). In part, these
alterations occur due to low functional capacity resulting
from uremic syndrome and a high sedentary index (3). The
reduction of functional capacity evaluated by the 6MWT
was observed in several studies of patients with pulmonary
hypertension and HF (6,28), demonstrating the prognostic
and predictive value of the 6MWT for mortality (6,11,18).
Our study demonstrates that the distance walked in the
6MWT is also an independent mortality factor in end-stage
renal disease patients.
The VO2 peak value and the distance walked in the
6MWT have been noted as strong independent predictors of
mortality in HF (29) patients. Sietsema et al. (3), analyzing
the VO2 peak and life expectancy in ESRD patients, stated
that values less than 17.5 mL/kg-1/min-1 are strong mor-
tality predictors. ESRD patients demonstrate an approxi-
mately 64% VO2 peak reduction compared with age-
matched control subjects (30). These results are similar to
the VO2 values obtained in our study, which were 50%
below the expected values.
The gold standard for functional capacity evaluation is
the VO2 peak, which is evaluated by the ergospirometric test
(31). However, this method requires a trained team and
specialized equipment, involves high cost and is not always
tolerated by terminal renal insufficiency patients, limiting
Table 1 - Clinic and biochemical characteristics of patients stratified by life expectancy and death.
Variables Sample (n = 52) Death (n = 21)
Life
Expectancy
(n= 31) p-value
Age (years) 36¡11 33.8¡12 38¡10 0.185
Male (%) 54 28.6 71 0.002*
BMI (kg/m2) 22¡4 22.4¡3.4 22¡4 0.518
HD time (months) 110¡59.3 92.3¡49 140¡58.1 0.168
Transplant (%) 23.1 52.4 3.2
SBP (mmHg) 157.6¡26.6 146.2¡23.2 165.4¡29 0.01*
DBP (mmHg) 96¡19.3 91.7¡17 99¡20 0.193
ESRD-SI 7.5¡5.5 5¡4 9.3¡6 0.002*
Urea (mg/dL) 146.5¡38 145.0¡36.6 147.4¡40 0.845
Creatinine (mg/dL) 9.4¡1.3 9.3¡1.5 9.4¡1.3 0.424
Calcium (mg/dL) 8.6¡1.1 9.1¡2.5 9.6¡4 0.656
Phosphorus (mg/dL) 6¡2.2 5.4¡1.7 6¡2 0.282
HT (%) 26.5¡5.1 26.1¡5 27¡5.4 0.435
HG (g/dL) 8.6¡1 8.6¡0.6 8.7¡0.5 0.649
HBsAg + (Elisa) (%) 5.7 4.7 9.6 0.568
HCV + (EIE) (%) 13.4 4.7 19.3 0.149
Digitalis (%) 46 57 42 0.212
Nitrates (%) 5.7 0 9.6 0.155
Beta-adrenergics (%) 11.5 5 16 0.233
Adrenergic central action (%) 17.3 14.3 16 0.914
Calcium antagonists (%) 36.5 52.4 26 0.037*
6MWT (meters) 517.1¡144 477.3¡119 525¡121.5 0.168
VO2 peak (obtained) (mL/kg
-1/min-1) 20.1¡ 8 21.6¡7.5 19.2¡8 0.270
VO2 peak (expected) (mL/kg
-1/min-1) 34.2¡8# 39¡7 31.3¡7 0.001*
Values are presented as the mean¡standard deviation. HD, hemodialysis; ESRD-SI, End-Stage Renal Disease Severity Index; 6MWT, six-minute walk test;
BMI, body mass index; VO2 peak, peak oxygen consumption; SBP, systolic blood pressure; DBP, diastolic blood pressure; HT, hematocrit; HG, hemoglobin;
HBsAg, hepatitis B surface antigen; HCV, hepatitis C antibodies; *p,0.05; #p,0.001.
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its large-scale use in this population (26,32). Our results
demonstrate that the 6MWT presents a moderate correlation
with the VO2 peak obtained in this evaluation. In clinical
experiments carried out with HF patients (NYHA class: II
and III) who were followed for a 6-month period, functional
capacity, measured by the ergospirometric test, showed a
moderate correlation with the distance walked in the 6MWT
and the life expectancy of these patients (33). It is important
to note that Gayda et al. (15), Guyatt et al. (34), and Lipkin
et al. (16) suggest a strong correlation between these
variables in cardiac patients. Our group previously showed
a moderate correlation between the distance walked and the
VO2 peak in patients with ESRD (35). However, it is also
important to highlight that there are no papers in the
literature establishing the prognostic value of the 6MWT in
these patients.
Anemia is an important complication in ESRD patients
and is associated with disease severity (36,37). In our study,
all of the patients with anemia were treated in accordance
with Diretrizes Brasileiras de Doenc¸a Renal Croˆnica (38).
Moreover, the hematocrit and hemoglobin values were
similar between ‘‘death’’ and ‘‘life expectancy’’, suggesting
that this variable did not influence our results.
Thus, our results suggest that the 6MWT can be
recommended as a viable, low-cost, easy-to-apply and
highly accurate alternative for the determination of the
functional capacity of ESRD patients.
In the analysis of the distance walked during the 6MWT
with 100-meter increments, our findings show that the
shorter the distance walked, the greater the probability of
death in terminal renal insufficiency patients. A similar
result was found by Rostagno et al. (39) when evaluating a
series of HF patients. Thus, performing physical activities
would improve the functional capacity and, consequently,
the distance walked, constituting a protection factor for
these types of patients (32). Due to the great prevalence of
comorbidities, any physical activity prescribed must follow
the principle of specificity and account for the functional
capacity of the patients to avoid adversely affecting their
health status (13). Based on our study, the distance obtained
in the 6MWT may be considered as a reliable alternative to
elaborate community rehabilitation programs for ESRD
patients and a method of evaluating the physical capacities
of these patients. The latter recommendation has already
been adopted for the management of patients with HF (40).
This study is potentially limited by the sample size, which
was reduced due to the difficulty of adherence of the
subjects to the proposed evaluations and the loss of patients
during the follow-up period. Another limitation is the
Figure 1 - Flowchart of the patients allocated in the study.
Table 2 - Cox univariate analysis stratified per 100 meters.
Variables OR 95% CI HR p-value
6MWT 0.79 0.62 – 1.01 0.064
Age 1.03 0.99 – 1.07 0.090
ESRD-SI 1.15 1.08 – 1.23 0.000*
HD time 1.01 1.00 – 1.02 0.003*
VO2 peak 0.96 0.91 – 1.01 0.122
OR, odds ratio; 6MWT, six-minute walk test stratified per 100 meters;
ESRD-SI, End-Stage Renal Disease Severity Index; HD, hemodialysis; VO2
peak, peak oxygen consumption; CI, confidence interval; HR, hazard ratio;
*p,0.05.
Table 3 - Cox multivariate analysis stratified by 100-meter
increments.
Variables OR 95% CI HR p-value
6MWT 0.53 0.37 – 0.74 0.000*
Age 1.28 1.16 – 1.41 0.000*
ESRD-SI 1.01 1.00 – 1.02 0.001*
HD time 1 0.94 – 1.03 0.651
VO2 peak 1.04 0.97 – 1.13 0.259
OR, odds ratio; 6MWT-100, distance walked in six-minute walk test
stratified by 100 meters; ESRD-SI, End-Stage Renal Disease Severity Index;
HD, hemodialysis; VO2 peak, peak oxygen consumption; CI, confidence
interval; HR, hazard ratio; *p,0.05.
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possibility that only a single measure of distance walked in
the 6MWT may not accurately represent the real functional
capacity of the individuals. However, in patients with
chronic renal insufficiency, a previous study (41) showed
only a 3.7% increase in the distance walked when the test
was repeated after 48 h. Additionally, it was not possible to
determine the cause of death of some patients because the
registries presented the cause of death simply as HF, which
renders it difficult to analyze the data.
In conclusion, the distance walked in the 6MWT,
hemodialysis time and ESRD-SI were predictors of the life
expectancy of ESRD patients. The 6MWT is an accessible
tool for determining functional capacity that is reliable and
easy to apply. Furthermore, it may be used as a strategy to
identify the progression and aggravation of the disease and,
consequently, the death risk in terminal renal insufficiency
patients. Therefore, its incorporation into clinical practice
and the follow up of patients with chronic nephropathy in
hemodialysis programs is recommended.
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